Table 3.
Characteristics associated with lack of symptomatic control.
| Characteristic, n (%) | Stopped at 6 months (n = 35) | p-value | Stopped at 12 months (n = 49) | p-value |
|---|---|---|---|---|
| Age ⩾ 75 | 5 (14.3) | 0.361 | 8 (16.3) | 0.095 |
| Age ⩾ 65 | 15 (42.9) | 0.514 | 16 (32.7) | 0.326 |
| Female | 24 (68.5)* | 0.004 | 28 (57.1) | 0.087 |
| Failed amiodarone | 3 (8.6) | 0.729 | 5 (10.2) | 0.510 |
| Failed sotalol | 3 (8.6) | 0.247 | 5 (10.2) | 0.285 |
| Failed dronedarone | 9 (25.7)* | 0.020 | 8 (16.3) | 0.425 |
| Failed dofetilide | --- | 1.00 | --- | 1.00 |
| Failed propafenone | 4 (11.4) | 0.06 | 5 (10.2)* | 0.045 |
| Prior cardioversion | 10 (28.6) | 0.904 | 16 (32.7) | 0.348 |
| Diltiazem use | 10 (28.6) | 0.555 | 16 (32.7) | 1.00 |
| Atenolol use | 5 (14.3)* | 0.039 | 5 (10.2) | 0.274 |
| Nebivolol use | --- | 0.336 | --- | 0.096 |
| Labetalol use | --- | 1.00 | --- | 1.00 |
| Metoprolol tartrate use | 5 (14.3) | 0.954 | 8 (16.3) | 0.670 |
| Metoprolol succinate use | 7 (20.0) | 0.716 | 10 (20.4) | 0.707 |
| Carvedilol use | 2 (5.7) | 0.248 | 2 (4.1) | 0.605 |
| Digoxin use | 5 (14.3) | 0.306 | 6 (12.2) | 0.366 |
| Hypertension | 24 (68.5)* | 0.040 | 28 (57.1) | 0.526 |
| Diabetes | 4 (11.4) | 0.463 | 5 (10.2) | 0.510 |
| Stroke or TIA | --- | 1.00 | --- | 0.551 |
| Vascular disease or CAD | 3 (8.6) | 0.729 | 4 (8.2) | 1.00 |
| CKD | --- | 1.00 | --- | 1.00 |
| COPD | --- | 0.572 | --- | 0.300 |
| OSA | 4 (11.4) | 1.00 | 6 (12.2) | 0.756 |
| ICD | --- | 1.00 | --- | 0.548 |
*
Statistical significance
CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disorder; ICD, implantable cardiac defibrillator; OSA, obstructive sleep apnea; TIA, transient ischemic attack.